Coya Therapeutics, Inc. Overview
Pro stress-test →Coya Therapeutics is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. The company is advancing COYA 302, a biologic combination intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease.
Strategic Profile
Pro stress-test →The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. In January 2026, the company completed an $11.1 million private placement with Dr. Reddy's Laboratories (a strategic collaborator) investing $10 million.
Competitive Landscape
Pro stress-test →Coya competes in the neurodegenerative disease space against larger pharma companies and clinical-stage biotech competitors developing for ALS, FTD, and Parkinson's disease. The company's Treg immunology approach is differentiated from conventional small-molecule and monoclonal antibody approaches. Key competitive reference points include other Treg-focused therapies and traditional neurodegenerative disease treatments, though the novel mechanism positions Coya distinctly.
Industry Context
Coya Therapeutics, Inc. operates in Clinical-Stage Biotechnology / Specialty Pharmaceuticals - Neurodegenerative Disease Therapeutics.
Key facts
Founded: 2020 · Headquarters: Houston, Texas